2026 Exhibitors & Sponsors
Thank you to our 2026 Supporters!
Sponsor
https://www.wiley.com/en-us/publish/article/author-resources/
Wiley champions those who see knowledge as a force for good. A trusted leader in research and learning, our pioneering solutions and services are paving the way for knowledge seekers as they work to solve the world’s most important challenges. Around the globe, we break down barriers for innovators, empowering them to publish and advance discoveries in their fields, evolve their workforces, and shape minds through teaching and learning. Together, we are unlocking the creation and curation of knowledge for all, transforming today’s biggest obstacles into tomorrow’s brightest opportunities.Exhibitors
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit argenx.com
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. Axsome delivers scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Their industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple early and late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States.
Since its inception in 1992, Medeia Inc. has been at the forefront of the manufacture and distribution of neurodiagnostic and heart rate variability/ANS products. Medeia Inc. specializes in the development of state-of-the-art biometrical software and hardware products intended to monitor physiology for research and educational purposes.